These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29107280)

  • 1. Castration-Resistant Prostate Cancer: An Algorithmic Approach.
    Stratton K; Cookson M
    Urol Clin North Am; 2017 Nov; 44(4):647-655. PubMed ID: 29107280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.
    Ponholzer A; Loidl W; Bektic J; Dorfinger K; Hruby S; Jeschke K; Kramer G; Krause S; Ludvik G; Remzi M; Roider M; Stoiber F
    Wien Klin Wochenschr; 2016 Feb; 128(3-4):156-63. PubMed ID: 26831188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endocrine therapy for prostate cancer.].
    Nagaya N; Horie S
    Clin Calcium; 2018; 28(11):1527-1533. PubMed ID: 30374010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
    Küronya Z; Bíró K; Gyergyay F; Géczi L
    Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
    Hakariya T; Sakai H
    Nihon Rinsho; 2016 Jan; 74(1):137-42. PubMed ID: 26793894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the mechanisms of progression in castration-resistant prostate cancer.
    Ceder JA
    Eur Urol; 2015 Mar; 67(3):480-1. PubMed ID: 25465967
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
    Luo J; Beer TM; Graff JN
    Oncology (Williston Park); 2016 Apr; 30(4):336-44. PubMed ID: 27085332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
    Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alternative antiandrogen therapy for castration-resistant prostate cancer].
    Suzuki H; Utsumi T; Endo T; Kamijima S; Kamiya N
    Nihon Rinsho; 2016 May; 74 Suppl 3():589-94. PubMed ID: 27344799
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile.
    Angulo JC; Andrés G; Ashour N; Sánchez-Chapado M; López JI; Ropero S
    J Urol; 2016 Mar; 195(3):619-26. PubMed ID: 26551297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of the AUA Castration Resistant Prostate Cancer Guidelines into Practice: Establishing a Multidisciplinary Clinic.
    Stratton KL; Moeller AM; Cookson MS
    Urol Pract; 2016 May; 3(3):203-209. PubMed ID: 37592460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.